Rockefeller Capital Management
STOK icon

Rockefeller Capital Management’s Stoke Therapeutics STOK Stock Holding History

Rockefeller Capital Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.7K Hold
481
– – ﹤0.01% 3824
2026
Q1 		$15.7K Buy
481
+383
+391% +$12.6K ﹤0.01% 3804
2025
Q4 		$3.11K Buy
+98
New +$2.95K ﹤0.01% 4207

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Rockefeller Capital Management's STOK Position: Q2 2026 in Review

Rockefeller Capital Management held its Stoke Therapeutics (STOK) position steady in Q2 2026 at 481 shares worth $15.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3824.

Rockefeller Capital Management first reported a position in STOK in Q4 2025 and has held it in 3 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Rockefeller Capital Management held 481 shares of Stoke Therapeutics worth $15.7K as of Q2 2026.
  • Rockefeller Capital Management left its Stoke Therapeutics share count unchanged in Q2 2026.
  • Stoke Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3824 holding.
  • Rockefeller Capital Management first reported a position in Stoke Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.